Physician profile
Gary W Young
NPI 1689601155
$1,830.33
in general payments reported to CMS, 2019-2025
21 companies · $553 in 2025
The $553 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $586 · 2020: $183 · 2021: $19.09 · 2022: $20.13 · 2023: $103 · 2024: $366 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,022.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,022.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $273.46 | 2019-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $230.71 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $179.42 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $177.03 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $168.77 | 2019-2025 | |
| Glaxosmithkline, LLC. | $115.48 | 2019-2021 | |
| Amgen INC. | $107.78 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $78.73 | 2019-2023 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.49 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $66.89 | 2019 | |
| Alk-Abello, INC | $62.56 | 2025 | Grastek, Odactra, Ragwitek |
| Dexcom, INC. | $54.48 | 2024 | Dexcom G6 Transmitter |
| Abbvie INC. | $42.04 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $34.78 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.51 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $29.64 | 2019 | |
| Axsome Therapeutics, INC. | $27.42 | 2025 | Auvelity |
| Actelion Pharmaceuticals US, INC. | $23.44 | 2023 | Uptravi, Opsumit |
| Circassia INC. | $22.69 | 2019 | |
| Corcept Therapeutics | $20.57 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $14.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.